Vapor
Recently TwinStrand Biosciences, Inc. announced that it filed a patent infringement lawsuit against Guardant Health, Inc. (Nasdaq: GH). TwinStrand and its exclusive licensor, the University of Washington, filed the lawsuit in the United States District Court in Delaware. A copy of the complaint is available in the News section of TwinStrand’s website.
The complaint alleges that Guardant Health infringes
multiple patents covering TwinStrand’s proprietary Duplex Sequencing
methods for generating highly accurate DNA sequence data. The methods
described and claimed in TwinStrand’s patents enable
clinically-actionable sequence data to be generated by analyzing
fragments of DNA in blood samples or other tissues. The technology was
invented by TwinStrand’s CEO, Jesse Salk, M.D., Ph.D., and his
colleagues at the University of Washington, and is exclusively licensed
to TwinStrand.
TwinStrand is seeking remedies including a
permanent injunction against Guardant Health’s use and sale of
Guardant’s infringing products and services, as well as compensatory and
enhanced damages for past infringement.
“TwinStrand has a
powerful and growing portfolio of issued patents in the United States
and worldwide designed to protect its groundbreaking Duplex Sequencing
process which allows highly accurate DNA sequencing. We intend to pursue
this litigation vigorously and to protect our intellectual property
rights in the United States and globally,” said TwinStrand’s General
Counsel, Karen Dabbs.
In 2020, TwinStrand launched its first
commercial DuplexSeq™ kit, which uses TwinStrand’s patented DNA Duplex
Sequencing error correction approach to obtain unparalleled sensitivity
and specificity. “TwinStrand is committed to bringing its technology to
patients, clinicians, and researchers through its own products,
licensing, and other partnerships, but it will not allow the continued
infringement of its patents,” said Dabbs. “TwinStrand is also
considering its legal options against other parties who directly
infringe, or induce others to infringe, its patented technology,” Dabbs
added.
Source:www.morningstar.com
Editor:IPRdaily-Vapor